LMF
IMUC

LMR Master Fund’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

LMR Master Fund’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-4,159
Closed -$323K – 539
2013
Q2 		$323K Buy
+4,159
New +$398K 0.03% 323

Other funds holding IMUC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

LMR Master Fund's IMUC Position: Q3 2013 in Review

LMR Master Fund sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q3 2013, closing a stake of 4,159 shares — an estimated $323K sold.

LMR Master Fund first reported a position in IMUC in Q2 2013 and held it in 1 quarter. The position peaked at $323K in Q2 2013. 37 funds tracked by Wall St. Rank hold IMUC as of Q3 2013.

  • LMR Master Fund reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q3 2013 after selling out during the quarter.
  • LMR Master Fund sold 4,159 ImmunoCellular Therapeutics, Ltd. shares in Q3 2013, an estimated $323K.
  • LMR Master Fund first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 1 quarter.
  • LMR Master Fund's ImmunoCellular Therapeutics, Ltd. position peaked at $323K in Q2 2013.
  • 37 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q3 2013.

Based on LMR Master Fund's 13F filing for Q3 2013, filed 14 Nov 2013.